AstraZeneca Pharma India is divesting a 64-acre manufacturing facility in North Bengaluru for approximately Rs 3,400 crore, signaling a strategic operational shift. At the same time, the company faces heightened scrutiny regarding its COVID-19 vaccine, with new court documents revealing links to rare adverse events like thrombosis with thrombocytopenia. Despite these challenges, AstraZeneca is poised to seize growth opportunities in oncology with upcoming drug launches, including Tezepelumab and Enhertu, as it continues to navigate regulatory hurdles.
“AstraZeneca Pharma India is divesting a 64-acre manufacturing facility in North Bengaluru for approximately Rs 3,400 crore/Mkt Cap Rs 20000cr”
“Procès pour dommages vaccinaux contre AstraZeneca (AZ) : Décision marquante à Karlsruhe - Une médecin vaccinée et lésée a obtenu une victoire partielle devant la Cour fédérale de justice. AZ doit divulguer des données complètes et les tribunaux doivent autoriser les expertises de spécialistes.”
“That's not gene therapy. Gene therapy (like Gendicine) introduces genetic material to correct defective genes or restore function long-term in target cells. AZ is a transient vaccine platform, not therapeutic gene correction.”
“No established population-level data links COVID vaccines, including AstraZeneca, to increased dementia or Alzheimer's risk. Large cohorts (e.g., UK Biobank 2025 analysis) show infection itself raises new-onset vascular dementia odds by ~77% (HR 1.77) and all-cause dementia by 41%, driven by vascular inflammation—unvaccinated cases hit hardest.”
“Vaccination often mitigates this by curbing severe illness.”
“Rare post-AZ clot cases exist, but not tied to broad trends. Monitoring ongoing.”
“The move could position GSK closer to competitors such as AstraZeneca (NYSE:AZN), which has accelerated oncology development through multiple late-stage programs over recent years.”
“Additionally, the expected launch of emerging therapies such as Tezepelumab (TEZSPIRE) (AstraZeneca and Amgen) will further propel the market growth.”
“Key eosinophilic esophagitis companies, including AstraZeneca, Amgen, Ellodi Pharmaceuticals, and others, are actively working on innovative eosinophilic esophagitis drugs. These novel eosinophilic esophagitis therapies are anticipated to enter the eosinophilic esophagitis market in the forecast period.”
“In its Q3 2025 update presented in November 2025, AstraZeneca indicated that results from the CROSSING trial evaluating tezepelumab in Eosinophilic Esophagitis (EoE) are expected in the latter half of 2026.”
“Key Eosinophilic Esophagitis Companies AstraZeneca, Amgen, Ellodi Pharmaceuticals, Revolo Biotherapeutics, Phathom Pharmaceuticals, Uniquity Bio, EsoCap AG, DBV Technologies, Eupraxia Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Dr. Falk Pharma GmbH, Takeda, and others”
“Innovative therapies in the pipeline focus on bispecific antibodies and CAR-T constructs, with leading developments driven by companies like Roche and AstraZeneca.”